SENNA (SENNOSIDES) (sen'na) Black-Draught, Gentlax B, Senexon, Senokot, Senolax Classifications: stimulant laxative; Therapeutic: stimulant laxative Prototype: Bisacodyl Pregnancy Category: C |
8.6 mg, 15 mg, 25 mg tablets; 8.6 mg/5 mL, 15 mg/5 mL syrup
Prepared from dried leaflet of Cassia acutifolia or Cassia angustifolia. Senna glycosides are converted in colon to active aglycone, which stimulates peristalsis. Concentrate is purified and standardized for uniform action and is claimed to produce less colic than crude form.
Peristalsis stimulated by conversion of drug to active chemical.
Acute constipation and preoperative and preradiographic bowel evacuation.
Hypersensitivity; appendicitis, fecal impaction; fluid and electrolyte imbalances; irritable colon, nausea, vomiting, undiagnosed abdominal pain, intestinal obstruction; children <6 y; pregnancy (category C), lactation.
Diabetes mellitus; children >6 y; fluid and electrolyte imbalances.
Constipation Adult: PO Standard Senna Concentrate 12 tablets or ?1 tsp h.s. (max: 4 tablets or 2 tsp b.i.d.); Syrup, Liquid 1015 mL at h.s. Child: PO Standard Senna Concentrate >27 kg, 1 tablet or ? tsp h.s.; Syrup, Liquid 1 mo1 y, 1.252.5 mL h.s.; 15 y, 2.55 mL h.s.; 515 y, 510 mL h.s. |
Assessment & Drug Effects
Patient & Family Education